Siddhartha Yadav: A Missed Opportunity for 7500 Patients With Metastatic Breast Cancer
Siddhartha Yadav, Breast and Gynecologic Oncologist in the Women’s Cancer Program at Mayo Clinic Comprehensive Cancer Center, shared a post on X about recent paper he and his colleagues co-authored published in JCO Precision Oncology:
“Despite clear guidelines, germline genetic testing remains underutilized in patients with metastatic breast cancer.
In our new study published in JCO Precision Oncology, we evaluated >15,000 patients with metastatic breast cancer and found that fewer than half received germline BRCA1/2 testing.
This represents a missed opportunity—not just for personalized treatment, but also for cancer prevention in families.
How can we close this gap?”
Title: Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Authors: Siddhartha Yadav, Fergus J. Couch, Sam Hillman, Linlin Luo, Weiyan Li, Qixin Li, Jennifer Fallas Hayes, Jagadeswara R. Earla, Xiaoqing Xu
Read the Full Article on JCO Precision Oncology
More posts featuring Sid Yadav.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023